Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: Long term results from a prospective clinical trial

CONCLUSION: EPNI and a simultaneous hypofractionated prostate boost combined with long-term ADT for high-risk prostate cancer resulted in acceptable 10-year biochemical control and survival with low grade ≥3 toxicity.PMID:34324914 | DOI:10.1016/j.radonc.2021.07.018

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - July 29, 2021 Category: Radiology Authors: Rachel M Glicksman Andrew Loblaw Gerard Morton Ewa Szumacher Hans T Chung Danny Vesprini William Chu Stanley K Liu Richard Choo Andrea Deabreu Alexandre Mamedov Liying Zhang Patrick Cheung Source Type: research